Compare · BIIB vs IBRX
BIIB vs IBRX
Side-by-side comparison of Biogen Inc. (BIIB) and ImmunityBio Inc. (IBRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and IBRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $28.84B, about 4.0x IBRX ($7.25B).
- Over the past year, BIIB is up 43.6% and IBRX is up 109.2% - IBRX leads by 65.6 points.
- IBRX has been more active in the news (10 items in the past 4 weeks vs 9 for BIIB).
- BIIB has more recent analyst coverage (25 ratings vs 6 for IBRX).
- Company
- Biogen Inc.
- ImmunityBio Inc.
- Price
- $192.65-1.36%
- $7.17+3.68%
- Market cap
- $28.84B
- $7.25B
- 1M return
- +0.68%
- -7.42%
- 1Y return
- +43.59%
- +109.18%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 9
- 10
- Recent ratings
- 25
- 6
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
ImmunityBio Inc.
ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and glioblastoma. It also develops a memory T-cell cancer vaccine to deliver tumor-associated antigens and neoepitopes; and a human adenovirus 5 COVID-19 vaccine. The company was founded in 2014 and is based in San Diego, California.
Latest BIIB
- Biogen upgraded by Needham with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
- EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
- Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
- UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
- Stoke Therapeutics to Present at Upcoming Investor Conferences in June
- Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
- BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations
- Evercore ISI resumed coverage on Biogen
Latest IBRX
- Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
- Director Simon Barry J. sold $165,306 worth of shares (23,033 units at $7.18) as part of a pre-agreed trading plan, decreasing direct ownership by 0.81% to 2,827,788 units (SEC Form 4)
- The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
- ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
- The $13 Million Company Teaching the Immune System to Hunt Cancer
- ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
- Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
- ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
- ImmunityBio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure
- ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035